- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07188558
- Original rettssak
En studie for å undersøke Ronde-Cel versus Investigator's Choice CD19 CAR T-cellebehandling (PiNACLE-H2H)
En fase 3-randomisert kontrollert studie av Rondecabtagene Autoleucel, en autolog, dual-målrettet CD19/CD20 CAR T-celleproduktkandidat, kontra etterforskers valg av CD19 CAR T-cellebehandling hos pasienter med tilbakefall eller ildfast stor B-celle-lymfom i den andre linjen med pasienter med tilbakefall eller ildfast
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Studieoversikt
Status
Forhold
- Lymfom, B-celle
- Diffust storcellet B-celle lymfom refraktær
- Non-Hodgkin lymfom
- Refraktært non-Hodgkin lymfom
- Stort B-celle lymfom
- Diffust storcellet B-celle lymfom har fått tilbakefall
- Residiverende non-Hodgkin lymfom
- Diffust storcellet B-celle lymfom (DLBCL)
- Non-Hodgkin lymfom refraktært/ tilbakefall
Intervensjon / Behandling
Detaljert beskrivelse
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20 antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies, including axi-cel and liso-cel, still experience progressive disease, often due to mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate enriched for CD62L-positive naïve and central memory T cells, which are associated with enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct that can fully activate upon recognition of either CD19 or CD20, aiming to improve durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be administered as a single intravenous infusion following fludarabine and cyclophosphamide lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with long-term follow-up extending to 15 years.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Mary Lessig, MS
- Telefonnummer: 000-000-0000
- E-post: clinicaltrials@lyell.com
Studer Kontakt Backup
- Navn: James Dean, MD, PhD
- Telefonnummer: 000-000-0000
- E-post: clinicaltrials@lyell.com
Studiesteder
-
-
Queensland
-
Douglas, Queensland, Australia, 4814
- Rekruttering
- Townsville University Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Rekruttering
- The Alfred
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- Princess Margaret Cancer Centre
-
-
-
-
Arizona
-
Gilbert, Arizona, Forente stater, 85234
- Rekruttering
- Banner MD Anderson Cancer Center
-
Scottsdale, Arizona, Forente stater, 85258
- Rekruttering
- Honor Health
-
Scottsdale, Arizona, Forente stater, 85259
- Rekruttering
- Mayo Clinic Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Har ikke rekruttert ennå
- University of Arkansas
-
-
California
-
Los Angeles, California, Forente stater, 90048
- Rekruttering
- Cedars-Sinai Medical Center
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- University of California, Los Angeles (UCLA)
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California, Irvine
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- Colorado Blood Cancer Institute
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- Rekruttering
- MedStar Georgetown University Hospital
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic Florida
-
Orlando, Florida, Forente stater, 32804
- Rekruttering
- AdventHealth
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Rekruttering
- Northside Hospital
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa
-
-
Kansas
-
Westwood, Kansas, Forente stater, 66205
- Rekruttering
- University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- University of Louisville Health
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Rekruttering
- Tufts Medical Center
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68105
- Rekruttering
- University of Nebraska Medical Center (UNMC)
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- Hackensack
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Atlantic Health
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87102
- Rekruttering
- University of New Mexico Comprehensive Cancer Center
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Rekruttering
- Roswell Park Comprehensive Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Duke Cancer Institute
-
Winston-Salem, North Carolina, Forente stater, 27157
- Har ikke rekruttert ennå
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- Rekruttering
- University of Cincinnati
-
Cincinnati, Ohio, Forente stater, 45242
- Rekruttering
- Oncology Hematology Care Clinical Trials
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinical Taussig Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Har ikke rekruttert ennå
- Allegheny Health Network
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forente stater, 78704
- Rekruttering
- St. David's South Austin Medical Center
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- University of Texas Southwestern Medical Center
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
San Antonio, Texas, Forente stater, 78229
- Rekruttering
- Texas Transplant Institute
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84143
- Rekruttering
- Intermountain Healthcare
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
Richmond, Virginia, Forente stater, 23298
- Rekruttering
- Virginia Commonwealth University-Massey Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Rekruttering
- Medical College of Wisconsin
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
-
CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
-
Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
-
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
-
Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
-
Adequate hematological, renal, hepatic, pulmonary, and cardiac function
Key Exclusion Criteria:
- Patients ineligible to receive CD19 CAR T-cell therapy
- Primary CNS lymphoma
- Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter's transformation)
- Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years
- Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment
- Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Rondecabtagene Autoleucel
|
An autologous, dual-targeting CD19/20 CAR T-cell candidate.
Andre navn:
|
|
Aktiv komparator: Investigator's Choice CD19
axicabtagene ciloleucel, lisocabtagene maraleucel |
An autologous CD19 CAR T-cell therapy
Andre navn:
An autologous CD19 CAR T-cell therapy
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Event free survival
Tidsramme: 36 months
|
The time interval from treatment initiation until the occurrence of a specific event of interest. |
36 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate
Tidsramme: 36 months
|
Best Overall Response per Lugano Criteria |
36 months
|
|
Complete Response Rate
Tidsramme: 36 months
|
Complete Response per Lugano Criteria |
36 months
|
|
Progression Free Survial
Tidsramme: 36 months
|
The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. |
36 months
|
|
Overall Survival
Tidsramme: 6 years
|
The length of time from either the date of diagnosis or the start of treatment for a disease, that patients diagnosed with the disease, are still alive. |
6 years
|
|
Incidence and severity adverse events
Tidsramme: 36 months
|
To assess safety defined as type and frequency of AEs, serious adverse events (SAEs), and laboratory abnormalities. |
36 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LYL314-102
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .